Dr Reddys Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Dr Reddys Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 1258.9, up 0.01% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.15% on the day, quoting at 26164.95. The Sensex is at 85592.35, down 0.13%. Dr Reddys Laboratories Ltd has added around 5.26% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has added around 1.94% in last one month and is currently quoting at 22998.3, down 0.52% on the day. The volume in the stock stood at 9.23 lakh shares today, compared to the daily average of 16.06 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 1263.2, down 0.14% on the day. Dr Reddys Laboratories Ltd is up 3.04% in last one year as compared to a 7.78% gain in NIFTY and a 1.9% gain in the Nifty Pharma index.

The PE of the stock is 19.45 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

AVT03 is a human monoclonal IgG2 antibody and biosimilar candidate to Prolia and Xgeva, which are both denosumab but in different presentations.

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term treatment with systemic glucocorticoid.

Xgeva is a prescription medicine used to prevent bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone.

The EC decision is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

In May 2024, Dr. Reddy?s and Alvotech entered into a license and supply agreement for the commercialization of AVT03. Under the agreement, Alvotech will develop and manufacture AVT03, while Dr. Reddy?s is responsible for registration and commercialization in applicable markets, including the U.S. and Europe.

Hyderabad-based Dr. Reddy?s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company?s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

Powered by Capital Market - Live News

Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia? (denosumab) and Xgeva? (denosumab).

Prolia? is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term treatment with systemic glucocorticoid. Xgeva? is a prescription medicine used to prevent bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone.

The EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) adopted in September 2025 and was based on a totality of evidence, including analytical comparisons, pharmacokinetic and pharmacodynamic data, and outcomes from a confirmatory clinical trial. The EC decision is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

In May 2024, Dr. Reddy's and Alvotech entered into a license and supply agreement for the commercialization of AVT03. Under the agreement, Alvotech will develop and manufacture AVT03, while Dr. Reddy's is responsible for registration and commercialization in applicable markets, including the U.S. and Europe. Dr. Reddy's commercialization rights are exclusive for the U.S., and semi-exclusive for Europe and the UK. Upon approval Dr. Reddy's will offer the biosimilar under the tradenames Acvybra? (denosumab) 60 mg/mL solution for injection in a pre-filled syringe and Xbonzy? (denosumab) 70 mg/mL solution for injection in a vial.

Powered by Capital Market - Live News

Dr Reddys Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1247.5, up 0.12% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.3% on the day, quoting at 25987.2. The Sensex is at 84855.04, up 0.35%. Dr Reddys Laboratories Ltd has dropped around 2.69% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has dropped around 1.84% in last one month and is currently quoting at 22821.05, up 0.14% on the day. The volume in the stock stood at 5.21 lakh shares today, compared to the daily average of 20.79 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 1245.5, down 0.09% on the day. Dr Reddys Laboratories Ltd is up 4.52% in last one year as compared to a 10.8% spurt in NIFTY and a 6.08% spurt in the Nifty Pharma index.

The PE of the stock is 19.25 based on TTM earnings ending September 25.

Powered by Capital Market - Live News